How do the top 12 pharmaceutical companies operate safety pharmacology?

Journal of Pharmacological and Toxicological Methods

Volumn 66, Issue 2, 2012, Pages 66-70

  Ewart, Lorna ^a   Gallacher, David J ^b   Gintant, Gary ^c   Guillon, Jean Michel ^d   Leishman, Derek ^e   Levesque, Paul ^f   McMahon, Nick ^g   Mylecraine, Lou ^c   Sanders, Martin ^h   Suter, Willi ⁱ   Wallis, Rob ^j   Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

^b Center of Excellence for Cardiovascular Safety Research and Mechanistic Pharmacology   (Belgium)

^c Dept of Integrative Pharmacology ^*

^d SANOFI   (France)

^e ELI LILLY AND COMPANY   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h HOFFMANN LA ROCHE INC   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j PFIZER INC   (United States)

more..

Author keywords

Drug development; Drug discovery; Pharmac eutical company

Indexed keywords

ARTICLE; DRUG INDUSTRY; HEALTH CARE POLICY; IN VITRO STUDY; IN VIVO STUDY; PHARMACODYNAMICS; PHARMACOLOGY; PROBLEM SOLVING; PUBLICATION; QUESTIONNAIRE; RESPONSIBILITY; SAFETY; SCREENING TEST;

DATA COLLECTION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; INCOME; OUTSOURCED SERVICES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY; TOXICITY TESTS;

EID: 84865617951     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2012.03.004     Document Type: Article

References (19)

1. Anonymous ICHS7A: Safety pharmacology studies for human pharmaceuticals. London CPMP/ICH/539/00. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002831.pdf.
2. Bass A.S., Vargas H.M., Valentin J.P., Kinter L.B., Hammond T., Wallis R., et al. Safety Pharmacology in 2010 and beyond: Survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods 2011, 64:7-15.
3. Breckenridge A. A clinical pharmacologist's view of drug toxicity. British Journal of Clinical Pharmacology 1996, 42(1):53-58.
4. Faller B., Wang J., Zimmerlin A., Bell L., Hamon J., Whitebread S., et al. High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis. Expert Opinion on Drug Metabolism & Toxicology 2006, 2(6):823-833.
5. Friedrichs G.S., Patmore L., Bass A. Non-clinical evaluation of ventricular repolarization (ICH S7B): Results of an interim survey of international pharmaceutical companies. Journal of Pharmacological and Toxicological Methods 2005, 52:6-11.
6. Kaitin K.I., DiMasi J.A. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clinical Pharmacology and Therapeutics 2011, 89:183-188.
7. Kennedy T. Managing the drug discovery/development interface. Drug Discovery and Development 1997, 2:436-444.
8. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Reviews. Drug Discovery 2004, 3:711-715.
9. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. JAMA: The Journal of the American Medical Association 2002, 287:2215-2220.
10. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. Journal of the American Medical Association 1998, 279(15):1200-1205.
11. Leishman D.J., Beck T.W., Dybdal N., Gallacher D.J., Guth B.D., Holbrook M., Roche B., Wallis R.M. Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society. Journal of Pharmacological and Toxicological Methods 2012, 65:93-101.
12. Lindgren S., Bass A.S., Briscoe R., Bruse K., Friedrichs G.S., Kallman M.J., et al. Benchmarking Safety Pharmacology regulatory packages and best practice. Journal of Pharmacological and Toxicological Methods 2008, 58:99-109.
13. Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Reviews. Drug Discovery 2009, 8:959-968.
14. Redfern W.S., Valentin J.P. Trends in Safety Pharmacology: Analysis of posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010. Journal of Pharmacological and Toxicological Methods 2011, 64:102-110.
15. Tollman P., Morieux Y., Murphy J.K., Schulze U. Identifying R&D outliers. Nature Reviews. Drug Discovery 2011, 10:653-654.
16. Trepakova E.S., Koerner J., Pettit S.D., Valentin J.P. A HESI consortium approach to assess the human predictive value of non-clinical repolarisation assays. Journal of Pharmacological and Toxicological Methods 2009, 60:45-50.
17. Valentin J.P., Bialecki R., Ewart L., Hammond T., Leishman D., Lindgren S., et al. A framework to assess the translation of safety pharmacology data to humans. Journal of Pharmacological and Toxicological Methods 2009, 60:152-158.
18. Valentin J.P., Hammond T. Safety and secondary pharmacology: Successes, threats, challenges and opportunities. Journal of Pharmacological and Toxicological Methods 2008, 58:77-87.
19. Vargas H.M., Bass A.S., Breidenbach A., Feldman H.S., Gintant G.A., Harmer A.R., et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. Journal of Pharmacological and Toxicological Methods 2008, 58:72-76.